Aims: To compare the effectiveness of combined phacoemulsification and viscogoniosynechialysis versus trabeculectomy alone in primary angle-closure glaucoma (PACG) with a coexisting cataract. Methods: Thirty-nine Chinese patients (39 eyes) were retrospectively analyzed: 19 patients underwent combined phacoemulsification and viscogoniosynechialysis (group 1), and 20 underwent trabeculectomy (group 2). In both groups, the intraocular pressure (IOP), the number of antiglaucoma medications, the best corrected visual acuity (BCVA), the central anterior chamber depth (ACD), the synechial/apposition angle closure (SAC), and the success rates were assessed. Results: The median follow-up periods were similar for both groups (10 months). At the last follow-up, the mean IOP was 14.09 ± 6.89 mm Hg and the mean number of antiglaucoma medications was 0.36 ± 0.59 in group 1; in group 2, the mean IOP was 16.48 ± 4.74 mm Hg (p = 0.066) and the mean number of antiglaucoma medications was 1.05 ± 0.99 (p = 0.025). In terms of the mean central ACD and the mean SAC, there were significant differences between the groups (p = 0.0000, respectively). Kaplan-Meier analysis revealed that the cumulative probability of success in group 1 was higher than that in group 2 (p = 0.0051). Conclusion: Compared to trabeculectomy, combined phacoemulsification and viscogoniosynechialysis resulted in a lower requirement for glaucomatous medications, a greater improvement in BCVA, and a higher cumulative probability that treatment would be successful among patients with PACG and coexisting cataracts.

Keywords:
Phacoemulsification, Viscogoniosynechialysis, Intraocular pressure, Primary angle-closure glaucoma
1.
Ang LP, Ang LP: Current understanding of the treatment and outcome of acute primary angle-closure glaucoma: an Asian perspective. Ann Acad Med Singapore 2008;37:210–215.
2.
Quigley HA, Congdon NG, Friedman DS: Glaucoma in China (and worldwide): changes in established thinking will decrease preventable blindness. Br J Ophthalmol 2001;85:1271–1272.
3.
Foster PJ, Johnson GJ: Glaucoma in China: how big is the problem? Br J Ophthalmol 2001;85:1277–1282.
4.
Alsagoff Z, Aung T, Ang LP, et al: Long-term clinical course of primary angle-closure glaucoma in an Asian population. Ophthalmology 2000;107:2300–2304.
5.
Tan AM, Loon SC, Chew PT: Outcomes following acute primary angle closure in an Asian population. Clin Experiment Ophthalmol 2009;37:467–472.
6.
Tsai HY, Liu CJ, Cheng CY: Combined trabeculectomy and cataract extraction versus trabeculectomy alone in primary angle-closure glaucoma. Br J Ophthalmol 2009;93:943–948.
7.
Mosaed S, Dustin L, Minckler DS: Comparative outcomes between newer and older surgeries for glaucoma. Trans Am Ophthalmol Soc 2009;107:127–133.
8.
Tham CC, Kwong YY, Leung DY, et al: Phacoemulsification versus combined phacotrabeculectomy in medically controlled chronic angle closure glaucoma with cataract. Ophthalmology 2008;115:2167–2173.e2.
9.
Tarongoy P, Ho CL, Walton DS: Angle-closure glaucoma: the role of the lens in the pathogenesis, prevention, and treatment. Surv Ophthalmol 2009;54:211–225.
10.
Kumar RS, Tantisevi V, Wong MH, et al: Plateau iris in Asian subjects with primary angle closure glaucoma. Arch Ophthalmol 2009;127:1269–1272.
11.
Wang J, Qu H, Tan J: A histological study on peripheral iris in primary angle closure glaucoma (in Chinese). Yan Ke Xue Bao 1993;9:106–109.
12.
Vizzeri G, Weinreb RN: Cataract surgery and glaucoma. Curr Opin Ophthalmol 2010;21:20–24.
13.
Wang T, Liu L, Li Z, Zhang S: Studies of mechanism of primary angle closure glaucoma using ultrasound biomicroscope. Zhonghua Yan Ke Za Zhi 1998;34:365–368.
14.
Liu DT, Lee VY, Chiu TY, Lam DS: Long-term intraocular pressure control after clear corneal phacoemulsification in glaucoma patients. J Cataract Refract Surg 2006;32:183.
15.
Wang N, Wu H, Fan Z: Primary angle closure glaucoma in Chinese and Western populations. Chin Med J 2002;115:1706–1715.
16.
Lai JS, Tham CC, Lam DS: The efficacy and safety of combined phacoemulsification, intraocular lens implantation, and limited goniosynechialysis, followed by diode laser peripheral iridoplasty, in the treatment of cataract and chronic angle-closure glaucoma. J Glaucoma 2001;10:309–315.
17.
Varma D, Adams WE, Phelan PS, Fraser SG: Viscogonioplasty in patients with chronic narrow angle glaucoma. Br J Ophthalmol 2006;90:648–649.
18.
Razeghinejad MR: Combined phacoemulsification and viscogoniosynechialysis in patients with refractory acute angle-closure glaucoma. J Cataract Refract Surg 2008;34:827–830.
19.
Zhu H, Wei R, Li Y, Cai J, Zhou H: The contribution of phacoemulsification to combined cataract and glaucoma surgery. Zhonghua Yan Ke Za Zhi 2000;36:95–97.
20.
Sihota R: Classification of primary angle closure disease. Curr Opin Ophthalmol 2011;22:87–95.
21.
Chen YH, Lu DW, Cheng JH, et al: Trabeculectomy in patients with primary angle-closure glaucoma. J Glaucoma 2009;18:679–683.
22.
Zhuo YH, Wang M, Li Y, et al: Phacoemulsification treatment of subjects with acute primary angle closure and chronic primary angle-closure glaucoma. J Glaucoma 2009;18:646–651.
23.
Di SS, Sabetti L, Taverniti L, et al: Phacoemulsification and intraocular lens implant in eyes with primary angle-closure glaucoma: our experience. Acta Ophthalmol Scand Suppl 2002;236:17–18.
24.
Razeghinejad MR, Rahat F: Combined phacoemulsification and viscogoniosynechialysis in the management of patients with chronic angle closure glaucoma. Int Ophthalmol 2010;30:353–359.
25.
Tham CC, Kwong YY, Leung DY, et al: Phacoemulsification vs phacotrabeculectomy in chronic angle-closure glaucoma with cataract complications. Arch Ophthalmol 2010;128:303–311.
26.
AGIS investigators: The advanced glaucoma intervention study. 8. Risk of cataract formation after trabeculectomy. Arch Ophthalmol 2001;119:1771–1779.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.